Literature DB >> 14672489

First-trimester sonographic screening for Down syndrome.

Fergal D Malone1, Mary E D'Alton.   

Abstract

Screening for Down syndrome is an important part of routine antenatal care. The most common screening method in the United States involves the assessment of a combination of factors: maternal age, multiple second-trimester serum markers, and second-trimester ultrasonography (as a so-called "genetic sonogram"). More recently, however, there has been significant interest in first-trimester methods of screening, including screening for first-trimester serum markers and the sonographic measurement of fetal nuchal translucency. Multiple studies have demonstrated that fetal nuchal translucency has the potential of being a very powerful predictor of fetal aneuploidy. However, for clinicians a large void remains between this knowledge and the practical issues that must be addressed prior to endorsing this form of screening for widespread use. This article provides an objective assessment of the literature describing nuchal translucency, as well as some adjunct first-trimester sonographic techniques, such as ductus venosus flow and nasal bone studies. Additionally, a detailed description of practical problems that might limit the implementation of this form of screening is presented.

Entities:  

Mesh:

Year:  2003        PMID: 14672489     DOI: 10.1016/j.obstetgynecol.2003.08.004

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  10 in total

Review 1.  First trimester ultrasound tests alone or in combination with first trimester serum tests for Down's syndrome screening.

Authors:  S Kate Alldred; Yemisi Takwoingi; Boliang Guo; Mary Pennant; Jonathan J Deeks; James P Neilson; Zarko Alfirevic
Journal:  Cochrane Database Syst Rev       Date:  2017-03-15

Review 2.  First and second trimester serum tests with and without first trimester ultrasound tests for Down's syndrome screening.

Authors:  S Kate Alldred; Yemisi Takwoingi; Boliang Guo; Mary Pennant; Jonathan J Deeks; James P Neilson; Zarko Alfirevic
Journal:  Cochrane Database Syst Rev       Date:  2017-03-15

Review 3.  Second trimester serum tests for Down's Syndrome screening.

Authors:  S Kate Alldred; Jonathan J Deeks; Boliang Guo; James P Neilson; Zarko Alfirevic
Journal:  Cochrane Database Syst Rev       Date:  2012-06-13

4.  The associations of nuchal translucency and fetal abnormalities; significance and implications.

Authors:  Shaista Salman Guraya
Journal:  J Clin Diagn Res       Date:  2013-03-20

Review 5.  "Down syndrome: an insight of the disease".

Authors:  Ambreen Asim; Ashok Kumar; Srinivasan Muthuswamy; Shalu Jain; Sarita Agarwal
Journal:  J Biomed Sci       Date:  2015-06-11       Impact factor: 8.410

6.  Segmental duplication-quantitative fluorescent-polymerase chain reaction: An approach for the diagnosis of Down syndrome in India.

Authors:  Ambreen Asim; Sarita Agarwal
Journal:  Turk J Obstet Gynecol       Date:  2018-03-29

Review 7.  First trimester serum tests for Down's syndrome screening.

Authors:  S Kate Alldred; Yemisi Takwoingi; Boliang Guo; Mary Pennant; Jonathan J Deeks; James P Neilson; Zarko Alfirevic
Journal:  Cochrane Database Syst Rev       Date:  2015-11-30

Review 8.  Urine tests for Down's syndrome screening.

Authors:  S Kate Alldred; Boliang Guo; Yemisi Takwoingi; Mary Pennant; Susanna Wisniewski; Jonathan J Deeks; James P Neilson; Zarko Alfirevic
Journal:  Cochrane Database Syst Rev       Date:  2015-12-10

Review 9.  Down Syndrome: Current Status, Challenges and Future Perspectives.

Authors:  Mohammad Kazemi; Mansoor Salehi; Majid Kheirollahi
Journal:  Int J Mol Cell Med       Date:  2016-08-10

Review 10.  Novel Approaches to an Integrated Route for Trisomy 21 Evaluation.

Authors:  Angelika Buczyńska; Iwona Sidorkiewicz; Anna Trochimiuk; Sławomir Ławicki; Adam Jacek Krętowski; Monika Zbucka-Krętowska
Journal:  Biomolecules       Date:  2021-09-08
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.